Search - tctmd.com

Displaying 921 - 940 of 1949

Sort: Relevancy | Date

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Presenter: A. Pieter Kappetein, Allan Schwartz, Mathew Williams

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Transcatheter Pulmonary Valve Replacement

Presenter: John G. Webb, Ajit Yoganathan, John P. Cheatham

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Tricuspid Valve Repair Technologies

Presenter: John G. Webb, Ajit Yoganathan, Scott Lim

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Mitral Valve Replacement and Repair Technologies

Presenter: John G. Webb, Ajit Yoganathan, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

The TAVR Development Journey: Lessons Learned and Drivers of Success

Presenter: John G. Webb, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Advertisement

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

FDA Perspectives

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Lessons Learned from Early FIH/EFS Trials: Transcatheter Pulmonary Valve Replacement

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Lessons Learned from Early FIH/EFS Trials: Tricuspid Valve Repair Technologies

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Lessons Learned from Early FIH/EFS Trials: Mitral Valve Replacement and Repair Technologies

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

The TAVR Development Journey: Lessons Learned and Drivers of Success

Intermediate-Risk Studies II: Updates From SURTAVI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content